Related Experiment Videos
Nicotinamide and insulin secretion in normal subjects
P J Bingley1, G Caldas, R Bonfanti
1Department of Diabetes and Metabolism, St Bartholomew's Hospital, London, UK.
Diabetologia
|July 1, 1993
Summary
Nicotinamide supplementation does not alter insulin secretion or glucose metabolism in healthy adults. This finding supports its use in clinical trials for preventing Type 1 diabetes.
Area of Science:
- Endocrinology
- Metabolic Research
- Clinical Nutrition
Background:
- Nicotinamide is investigated for prolonging beta-cell survival in Type 1 diabetes.
- Nicotinic acid, a related compound, affects insulin secretion and resistance.
- The impact of nicotinamide on insulin secretion in healthy individuals is unknown.
Purpose of the Study:
- To determine if nicotinamide affects insulin secretion and glucose kinetics in healthy adults.
- To establish the safety of nicotinamide for use in Type 1 diabetes prevention trials.
Main Methods:
- 10 healthy adults underwent intravenous glucose tolerance tests.
- Tests were conducted before and after 14 days of nicotinamide treatment (25 mg.kg-1.day-1).
- Measurements included acute and late insulin responses, basal insulin and glucose levels, and glucose disposal rates.
Main Results:
- Nicotinamide treatment did not significantly alter acute insulin response (0-10 min area or 1-3 min level).
- Basal insulin and glucose levels remained unaffected by nicotinamide.
- Glucose disposal rates and late insulin responses were also unchanged.
Conclusions:
- Nicotinamide does not impact insulin secretion or glucose kinetics in normal subjects.
- These findings support the suitability of nicotinamide for trials aimed at delaying or preventing Type 1 diabetes onset.